Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In an open multicenter trial (uncontrolled study) in 4,247 patients (49.1% male, 50.9% female; aged 17-89 years) with mild, moderate, or severe hypertension, the antihypertensive efficacy and in particular the tolerability of verapamil slow-release (SR) 240 mg (Isoptin RR) were studied. The dosage of the drug was adjusted to the therapeutic response; in 88.7% of the patients it was titrated according to the study protocol: 63.2% received constantly one SR tablet throughout the 6-week treatment period; in 15.6% the dosage was increased to one and a half tablet after 2 weeks, and in 9.9% to one tablet b.i.d. after a further 2 weeks. Monotherapy with verapamil SR 240 mg normalized diastolic blood pressure (less than or equal to 90 mm Hg) in 90% of the patients with mild hypertension, 77% of those with moderate, and 61% of those with severe hypertension. It was evident that blood pressure reduction was more pronounced the higher the baseline value. Cardiac and extracardiac tolerability of verapamil SR 240 mg was good. Mean heart rate was slightly reduced, none of the patients developed a second- or third-degree atrioventricular block. Side effects were reported by 480 of the 4,247 patients (11.3%). As expected, constipation (4.03%) was the predominant adverse reaction, followed by dizziness (3.65%), headache (1.54%), and other (less than 1%). In 217 patients (5.1%) therapy was discontinued prematurely, in 139 (3.27%) because of side effects.
 ...
PMID:Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. 247 86

Isoptin SR was used in 65 essential hypertensive patients. 240mg Isoptin SR (German Knoll Pharmaceutical company) per day was used in group A (35 cases) for 6 weeks, and in group B (30 cases) for 24 weeks, BP in group A and B decreased obviously in the first and second week after treatment. Marked effective rate and total effective rate were 65.7% and 74.3% respectively in group A, and 70.0% and 83.3% in group B. There were no significant changes of HR in group A before and after treatment while there was a decrease of HR in group B (P < 0.001). Left atrium (LA) decreased after 6 weeks in group A with an obvious increase of E/A ratio. There was significant decrease in LA, increase in E/A ratio, regression of IVS, LVPW and LVMI, but no changes in SV, CO, LVEF after 24 weeks of treatment of Isoptin SR in group B. E/A ratio was very sensitive and occurred earliest both in group A and group B. Side effects such as headache, dizziness, constipation, insomnia, peripheral oedema, sinus bradycardia occurred mainly in the first week of treatment. These symptoms disappeared gradually in the course of continued administration of Isoptin SR.
 ...
PMID:The effect of Isoptin SR on blood pressure, heart function and hypertrophy of left ventricle of hypertensive patients. 808 92

Arterial hypertension, especially when co-exists with ischemic heart disease, makes an important clinical and social problem. Necessity to continue a treatment during the whole patients life produces many problems for a patient himself as well as for a physician. Thus, for many years, researches have been carried out to find a medicine that would allow to fully control blood pressure for all day, would have minimal side-effects and could be administered once a day. Beside convertase inhibitors such as Prestarium and Gopten, calcium channel blockers, especially retard verapamil forms like Isoptin SR-240 and SR-120 seem to be the most appropriate medicines, especially when hypertension is accompanied by ischemic heart disease and dysrrythmias. The study was performed in 150 hypertensive patients who were administered Isoptin SR-240 once a day and Isoptin SR-120 twice a day. That dose was sufficient to normalize benign and mild hypertension in most patients. Decreased frequency of dyshrrytmias and chest pain relief were also observed. Trials to increase daily dose up to 360 mg were accompanied by evident side effects such as dizziness and constipations. Much more profitable was to join lower Isoptin dose with convertase inhibitors and diuretics.
 ...
PMID:[Isoptin SR-240 and SR-120 in ambulatory treatment of arterial hypertension]. 875 74